Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

× No keyword cloud information.

18 in total

Review 1. SRC: a century of science brought to the clinic.

Authors: Alexey Aleshin; Richard S Finn
Journal: Neoplasia Date: 2010-08 Impact factor: 5.715

2. Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.

Authors: Brendan Boyce; Lianping Xing
Journal: Clin Investig (Lond) Date: 2011-12-01

Review 3. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.

Authors: Emma H McCafferty; Sohita Dhillon; Emma D Deeks
Journal: Paediatr Drugs Date: 2018-12 Impact factor: 3.022

4. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Authors: Anna Spreafico; Kim N Chi; Srikala S Sridhar; David C Smith; Michael A Carducci; Peter Kavsak; Tracy S Wong; Lisa Wang; S Percy Ivy; Som Dave Mukherjee; Christian K Kollmannsberger; Mahadeo A Sukhai; Naoko Takebe; Suzanne Kamel-Reid; Lillian L Siu; Sebastien J Hotte
Journal: Invest New Drugs Date: 2014-05-03 Impact factor: 3.850

Review 5. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Authors: John Araujo; Christopher Logothetis
Journal: Cancer Treat Rev Date: 2010-03-11 Impact factor: 12.111

Review 6. Evolving role of bone biomarkers in castration-resistant prostate cancer.

Authors: Janet E Brown; Sheryl Sim
Journal: Neoplasia Date: 2010-09 Impact factor: 5.715

7. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Authors: Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos
Journal: Clin Lymphoma Myeloma Leuk Date: 2016-08

8. Dasatinib inhibits proinflammatory functions of mature human neutrophils.

Authors: Krisztina Futosi; Tamás Németh; Robert Pick; Tibor Vántus; Barbara Walzog; Attila Mócsai
Journal: Blood Date: 2012-03-12 Impact factor: 22.113

9. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.

Authors: Hichame Id Boufker; Laurence Lagneaux; Mehdi Najar; Martine Piccart; Ghanem Ghanem; Jean-Jacques Body; Fabrice Journé
Journal: BMC Cancer Date: 2010-06-17 Impact factor: 4.430

10. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation.

Authors: K Vandyke; S Fitter; A C W Zannettino
Journal: Blood Cancer J Date: 2011-02-04 Impact factor: 11.037